Matsumoto T, Ikeda K, Yamato H, Morita K, Ezawa I, Fukushima M, Nishii Y, Ogata E
Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.
Biochem J. 1988 Mar 15;250(3):671-7. doi: 10.1042/bj2500671.
The effect of 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] on 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] metabolism was examined in rats fed on a low-calcium diet. These rats exhibit hypocalcaemia, high urinary cyclic AMP excretion, a markedly elevated serum 1,25(OH)2D concentration and low serum concentrations of both 24,25(OH)2D and 25(OH)D. When the rats are treated orally with 1, 5 or 10 micrograms of 24,25(OH)2D3/100 g every day, there is a dramatic decrease in serum 1,25(OH)2D concentration in a dose-dependent manner concomitant with an increase in serum 24,25(OH)2D concentration. Serum calcium concentration and urinary cyclic AMP excretion are not significantly affected by the 24,25(OH)2D3 treatment, which suggests that parathyroid function is not affected by the 24,25(OH)2D3 treatment. The 25(OH)D3 1 alpha-hydroxylase activity measured in kidney homogenates is markedly elevated in rats on a low-calcium diet but is not affected by any doses of 24,25(OH)2D3. In contrast, recovery of intravenously injected [3H]1,25(OH)2D3 in the serum is decreased in 24,25(OH)2D3-treated rats. Furthermore, when [3H]1,25(OH)2D3 is incubated in vitro with kidney or intestinal homogenates of 24,25(OH)2D3-treated rats there is a decrease in the recovery of radioactivity in the total lipid extract as well as in the 1,25(OH)2D3 fraction along with an increase in the recovery of radioactivity in the water-soluble phase. These results are consistent with the possibility that 24,25(OH)2D3 has an effect on 1,25(OH)2D3 metabolism, namely that of enhancing the degradation of 1,25(OH)2D3. However, because a considerable proportion of the injected 24,25(OH)2D3 is expected to be converted into 1,24,25(OH)3D3 by renal 1 alpha-hydroxylase in 24,25(OH)2D3-treated rats, at least a part of the decrease in serum 1,25(OH)2D concentration may be due to a competitive inhibition by 24,25(OH)2D3 of the synthesis of 1,25(OH)2D3 from 25(OH)D3. Thus the physiological importance of the role of 24,25(OH)2D3 in regulating the serum 1,25(OH)2D concentration as well as the mechanism and metabolic pathway of degradation of 1,25(OH)2D3 remain to be clarified.
在喂食低钙饮食的大鼠中研究了24,25 - 二羟基维生素D3 [24,25(OH)2D3] 对1,25 - 二羟基维生素D3 [1,25(OH)2D3] 代谢的影响。这些大鼠表现出低钙血症、高尿环磷腺苷排泄、血清1,25(OH)2D浓度显著升高以及血清24,25(OH)2D和25(OH)D浓度降低。当每天给大鼠口服1、5或10微克/100克的24,25(OH)2D3时,血清1,25(OH)2D浓度呈剂量依赖性显著下降,同时血清24,25(OH)2D浓度升高。血清钙浓度和尿环磷腺苷排泄不受24,25(OH)2D3处理的显著影响,这表明甲状旁腺功能不受24,25(OH)2D3处理的影响。在低钙饮食的大鼠中,肾匀浆中测得的25(OH)D3 1α - 羟化酶活性显著升高,但不受任何剂量的24,25(OH)2D3影响。相反,在接受过24,25(OH)2D3处理的大鼠中,静脉注射的[3H]1,25(OH)2D3在血清中的回收率降低。此外,当[3H]1,25(OH)2D3与接受过24,25(OH)2D3处理的大鼠的肾或肠匀浆在体外孵育时,总脂质提取物以及1,25(OH)2D3组分中的放射性回收率降低,同时水溶性相中放射性回收率增加。这些结果与24,25(OH)2D3对1,25(OH)2D3代谢有影响的可能性一致,即增强1,25(OH)2D3的降解。然而,由于在接受过24,25(OH)2D3处理的大鼠中,预期相当一部分注射的24,25(OH)2D3会被肾1α - 羟化酶转化为1,24,25(OH)3D3,血清1,25(OH)2D浓度降低至少部分可能是由于24,25(OH)2D3对25(OH)D3合成1,25(OH)2D3的竞争性抑制。因此,24,25(OH)2D3在调节血清1,25(OH)2D浓度中的生理重要性以及1,25(OH)2D3的降解机制和代谢途径仍有待阐明。